What is HC Wainwright’s Estimate for TVTX Q3 Earnings?

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Research analysts at HC Wainwright lifted their Q3 2026 EPS estimates for shares of Travere Therapeutics in a report released on Wednesday, August 5th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of $0.10 per share for the quarter, up from their previous forecast of ($0.10). HC Wainwright currently has a “Buy” rating and a $67.00 target price on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($0.54) per share. HC Wainwright also issued estimates for Travere Therapeutics’ Q4 2026 earnings at $0.24 EPS, FY2027 earnings at $1.47 EPS, FY2028 earnings at $3.52 EPS, FY2029 earnings at $4.24 EPS and FY2030 earnings at $5.73 EPS.

Other equities research analysts have also issued reports about the company. Wells Fargo & Company raised their price objective on Travere Therapeutics from $50.00 to $65.00 and gave the stock an “overweight” rating in a research note on Friday, June 12th. Evercore set a $78.00 price target on Travere Therapeutics in a research note on Monday. Wall Street Zen downgraded Travere Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Canaccord Genuity Group increased their price target on shares of Travere Therapeutics from $62.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings downgraded shares of Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $61.67.

Travere Therapeutics Trading Down 1.1%

Shares of NASDAQ:TVTX opened at $60.21 on Wednesday. The company has a debt-to-equity ratio of 24.58, a quick ratio of 3.99 and a current ratio of 4.05. The stock has a market capitalization of $5.68 billion, a price-to-earnings ratio of -130.89 and a beta of 1.12. Travere Therapeutics has a 1-year low of $17.05 and a 1-year high of $66.24. The company has a 50 day moving average price of $55.54 and a 200 day moving average price of $41.83.

Insiders Place Their Bets

In related news, Director Timothy Coughlin sold 10,000 shares of the company’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $50.07, for a total transaction of $500,700.00. Following the completion of the sale, the director directly owned 56,250 shares of the company’s stock, valued at approximately $2,816,437.50. This represents a 15.09% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Roy D. Baynes sold 4,500 shares of the firm’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $50.00, for a total transaction of $225,000.00. Following the completion of the transaction, the director owned 41,500 shares in the company, valued at $2,075,000. The trade was a 9.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.44% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Travere Therapeutics

Several large investors have recently made changes to their positions in the business. State Street Corp increased its position in Travere Therapeutics by 47.8% in the 4th quarter. State Street Corp now owns 4,756,666 shares of the company’s stock worth $181,752,000 after buying an additional 1,538,827 shares during the period. Perceptive Advisors LLC lifted its holdings in shares of Travere Therapeutics by 12.7% during the fourth quarter. Perceptive Advisors LLC now owns 4,278,180 shares of the company’s stock worth $163,469,000 after buying an additional 483,565 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Travere Therapeutics by 27.4% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company’s stock valued at $41,203,000 after acquiring an additional 599,102 shares during the period. Renaissance Technologies LLC boosted its position in shares of Travere Therapeutics by 28.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,246,779 shares of the company’s stock valued at $85,849,000 after acquiring an additional 494,665 shares during the period. Finally, Rock Springs Capital Management LP boosted its position in shares of Travere Therapeutics by 2.1% in the fourth quarter. Rock Springs Capital Management LP now owns 2,210,322 shares of the company’s stock valued at $84,456,000 after acquiring an additional 45,549 shares during the period.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.